Kennedy and HHS to link use of Tylenol in pregnancy to autism, WSJ reports

U.S. Health Secretary Robert F. Kennedy Jr. is reportedly set to announce a potential link between Kenvue's (KVUE.N) Tylenol and autism in pregnant women, a claim that caused Kenvue shares to slump over 6%. The Wall Street Journal reported this without citing included evidence, noting a judge previously rejected similar claims in 2023, raising significant market and regulatory uncertainty for Kenvue and the broader over-the-counter pharmaceutical industry.

Analysis

Kenvue (KVUE) is facing significant near-term pressure following a Wall Street Journal report that U.S. Health Secretary Robert F. Kennedy Jr. intends to announce a potential link between its flagship Tylenol product and autism when used during pregnancy. The market's reaction was immediate and negative, with KVUE shares declining over 6%, reflecting the perceived threat to a major revenue stream. Critically, the report notes that the claims were presented without supporting evidence and follows a 2023 court decision that rejected similar allegations, introducing a high degree of uncertainty. The involvement of Secretary Kennedy, who formerly headed the anti-vaccine group Children's Health Defense, adds a political and activist dimension to the regulatory risk. The lack of immediate comment from either Kenvue or the Department of Health and Human Services (HHS) exacerbates the information vacuum, leaving the stock vulnerable to speculation and headline risk pending the formal release of the HHS report.

Key Decisions for Investors

• Investors should anticipate continued volatility in Kenvue (KVUE) shares and monitor for the official HHS report, as headline risk from a high-profile government announcement could depress consumer demand for Tylenol regardless of the scientific merits.
• Given the report lacks cited evidence and a judge previously dismissed similar claims, initiating new positions is highly speculative until the formal HHS findings and Kenvue's defensive strategy are clarified.
• The situation poses a potential contagion risk to the broader consumer health sector; portfolio managers should review holdings in companies with prominent over-the-counter products, particularly those used in prenatal care, for heightened regulatory or litigation exposure.